Drug · FAERS side-effect profile with label screen

Naftifine side effects: what 334 FDA adverse event reports show

Naftifine Hydrochloride · 5 reaction terms · 66 drug–reaction co-reports · data 2026-09-14

Drug class

Allylamine antifungal

FDA label, Indications wording of the closest related product

Label matched

Naftifine Hydrochloride (Naftifine Hydrochloride)

closest FDA label found for this product string; brand list suppressed because the label is a related product, not an exact match

Who reports

334 reports · 48% serious · 12 with death outcome · 50% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Naftifine Hydrochloride Cream is indicated for the treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organism Trichophyton rubrum . Naftifine Hydrochloride Cream is an allylamine antifungal indicated for the treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organism Trichophyton rubrum .

FDA label, Indications and Usage

What it is

Naftifine Hydrochloride Cream is a white to off-white cream for topical use only. Each gram of Naftifine Hydrochloride Cream contains 20 mg of naftifine hydrochloride (2%), a synthetic allylamine antifungal compound.

FDA label, Description section

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 3 strongest signals

Labeled adverse reaction 1Not in label — unassessed 2

What the badges mean

Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 2 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show: hide coding/lab/outcome terms hide indication terms unlabeled only hide PRR-only

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Blister	27	30.3 21.1–43.5ROR 32.8 · χ² 737 / p 2e-162	29.7 EB05 21.4 · IC025 +3.7 3/3 methods agree	Labeled adverse reaction exact term	serious PRR 13.3	no trial data cached
Skin exfoliation	26	19.6 13.6–28.4ROR 21.2 · χ² 443 / p 1e-98	19.4 EB05 13.8 · IC025 +3.2 3/3 methods agree	Not in label — unassessed	serious PRR 16.1	no trial data cached
Application site pain	6	17.1 7.7–37.8ROR 17.4 · χ² 76 / p 2e-18	13.7 EB05 5.1 · IC025 +1.5 3/3 methods agree	Not in label — unassessed	serious n=1	no trial data cached

Trial evidence (ClinicalTrials.gov)

Trial cross-check not yet run for this drug (ClinicalTrials.gov pull covers the 800 most-reported drugs first).

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Blister	27	30.3 21.1–43.5ROR 32.8 · χ² 737 / p 2e-162	29.7 EB05 21.4 · IC025 +3.7 3/3 methods agree	Labeled adverse reaction exact term	serious PRR 13.3	no trial data cached
Skin exfoliation	26	19.6 13.6–28.4ROR 21.2 · χ² 443 / p 1e-98	19.4 EB05 13.8 · IC025 +3.2 3/3 methods agree	Not in label — unassessed	serious PRR 16.1	no trial data cached
Application site pain	6	17.1 7.7–37.8ROR 17.4 · χ² 76 / p 2e-18	13.7 EB05 5.1 · IC025 +1.5 3/3 methods agree	Not in label — unassessed	serious n=1	no trial data cached
Application site erythema	4	9.5 3.6–25.3ROR 9.6 · χ² 23 / p 1e-6	5.6 EB05 2.2 · IC025 +0.5 3/3 methods agree	Not in label — unassessed	–	no trial data cached
Libido decreased (lower sex drive)	3	15.2 4.9–46.9ROR 15.3 · χ² 27 / p 1e-7	7.9 EB05 2.2 · IC025 +0.3 3/3 methods agree	Not in label — unassessed	serious PRR 10.7	no trial data cached

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

Skin exfoliation — n=26, PRR 19.6

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Naftifine?

In FDA FAERS, the most frequently co-reported reaction terms for Naftifine are blister, skin exfoliation, application site pain, application site erythema, libido decreased. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Naftifine have an FDA boxed warning?

No. The FDA label retrieved for Naftifine has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Naftifine causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

FDA label via openFDA (set ID a740fc0d-45b3-411f-9dfd-f3d637b8a95f, effective 20251114; matched on openfda.generic_name.exact:"NAFTIFINE HYDROCHLORIDE")
Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA count= aggregation, field patient.drug.openfda.generic_name.exact, 5 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction
Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
Seriousness and sex counts from openFDA count=serious, patient.patientsex, seriousnessdeath

Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.